Copyright: ©Author(s) 2026.
World J Psychiatry. Apr 19, 2026; 16(4): 116158
Published online Apr 19, 2026. doi: 10.5498/wjp.v16.i4.116158
Published online Apr 19, 2026. doi: 10.5498/wjp.v16.i4.116158
Table 1 Baseline characteristics of the study population (n = 126), n (%)
| Characteristic | Value |
| Age (years), median (range) | 56 (32-74) |
| Sex | |
| Male | 91 (72.2) |
| Female | 35 (27.8) |
| Etiology | |
| HBV | 111 (88.1) |
| HCV | 8 (6.3) |
| Non-viral | 7 (5.6) |
| Child-Pugh class | |
| A | 102 (81.0) |
| B | 24 (19.0) |
| ECOG PS | |
| 0 | 68 (54.0) |
| 1 | 50 (39.7) |
| 2 | 8 (6.3) |
| BCLC stage | |
| B | 47 (37.3) |
| C | 79 (62.7) |
| Tumor diameter (cm), median (range) | 7.2 (3.5-15.8) |
| Tumor number | |
| Single | 53 (42.1) |
| Multiple | 73 (57.9) |
| Portal vein tumor thrombus | 41 (32.5) |
| AFP (ng/mL), median (range) | 386 (3.2-21450) |
| Number of TACE procedures, median (range) | 2 (1-5) |
| Lenvatinib dose (mg/day) | |
| 12 | 78 (61.9) |
| 8 | 48 (38.1) |
- Citation: Liu JY, Liang ZH, Liu JL, Li L, Cui B, Li TG. Anxiety, depression, and quality of life in hepatocellular carcinoma treated with drug-eluting microspheres plus lenvatinib: A prospective study. World J Psychiatry 2026; 16(4): 116158
- URL: https://www.wjgnet.com/2220-3206/full/v16/i4/116158.htm
- DOI: https://dx.doi.org/10.5498/wjp.v16.i4.116158